Pacchiana Maria Vittoria, Capelletto Enrica, Carnio Simona, Gridelli Cesare, Rossi Antonio, Galetta Domenico, Montagna Elisabetta Sara, Bordi Paola, Ceribelli Anna, Cortinovis Diego, Scotti Vieri, Martelli Olga, Valmadre Giuseppe, Del Conte Alessandro, Miccianza Annamaria, Morena Raffaella, Rosetti Francesco, Di Maio Massimo, Ostacoli Luca, Novello Silvia
Department of Oncology, University of Turin, Orbassano, Italy.
Department of Oncology, University of Turin, Orbassano, Italy.
Clin Lung Cancer. 2017 Jul;18(4):381-387. doi: 10.1016/j.cllc.2016.10.002. Epub 2016 Nov 22.
Pemetrexed maintenance therapy (MT) after induction with platinum-based chemotherapy has recently become a common treatment strategy for advanced nonsquamous non-small-cell lung cancer (NSCLC). However, the benefits of MT should be weighed with consideration of the patients' perceptions and preferences. The aim of the present study was to evaluate patients' attitudes toward MT and to describe physicians' awareness of their patients' inclinations.
We administered a 12-question anonymous survey and the Distress Thermometer Questionnaire to patients with advanced or recurrent nonsquamous NSCLC. The survey was also distributed to the referring physicians.
From December 2014 to July 2015, 92 patients and 37 physicians were enrolled. All 92 patients completed the questionnaire at T0 (before starting chemotherapy) and 56.5% also did so at T1 (after completion of induction). The physicians completed the survey only at T0. Most patients had a positive attitude toward MT at both T0 (78.9%) and T1 (86.5%), and 100% of the physicians thought their patients would be in favor of MT. The physicians believed that their patients' attitudes toward MT would decrease proportionally with the reduction in the magnitude of the overall survival increase and expected benefits. The decrease expected by the physicians was much greater than that reported by the patients. This was especially true for an overall survival increase as small as 1 month (51.9% of patients accepting MT vs. 13.5% supposed by physicians) or when the only treatment benefit was radiologic tumor stabilization (69.3% of patients accepting MT vs. 37.8% supposed by physicians).
NSCLC patients have a generally positive attitude toward MT, which is not directly proportional to the expected benefits and greater than the attitude expected by physicians.
在以铂类为基础的化疗诱导治疗后,培美曲塞维持治疗(MT)最近已成为晚期非鳞状非小细胞肺癌(NSCLC)的一种常见治疗策略。然而,MT的益处应结合患者的认知和偏好来权衡。本研究的目的是评估患者对MT的态度,并描述医生对其患者倾向的认知。
我们对晚期或复发性非鳞状NSCLC患者进行了一项包含12个问题的匿名调查,并发放了痛苦温度计问卷。该调查也分发给了转诊医生。
2014年12月至2015年7月,共纳入92例患者和37名医生。所有92例患者在T0(开始化疗前)完成了问卷,56.5%的患者在T1(诱导治疗完成后)也完成了问卷。医生仅在T0完成了调查。大多数患者在T0(78.9%)和T1(86.5%)时对MT持积极态度,100%的医生认为他们的患者会赞成MT。医生认为,患者对MT的态度将随着总生存期增加幅度和预期益处的减少而成比例下降。医生预期的下降幅度远大于患者报告的下降幅度。当总生存期仅增加1个月(51.9%的患者接受MT,而医生预计为13.5%)或唯一的治疗益处是影像学肿瘤稳定时(69.3%的患者接受MT,而医生预计为37.8%),情况尤其如此。
NSCLC患者对MT总体持积极态度,这与预期益处不成正比,且大于医生预期的态度。